Targovax announces median and three-year overall survival for TG01 trial in resected pancreatic cancer
Oslo, Norway, 23 May 2019 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces median overall survival of 33.3 months and 38% three-year survival rate in the 32-patient phase I/II clinical trial evaluating TG01 in resected pancreatic cancer in combination with standard of care chemotherapy (gemcitabine). Targovax has previously reported median overall survival (mOS) of 33.1 months for the 19 patients in the first dosing cohort, as well as 72% two-year survival rate and 94% mutant RAS-